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Objectives The purpose of this study was to assess the safety and efficacy of recombinant human neuregulin-1 (rhNRG-1) in
chronic heart failure (CHF) patients.
Background Neuregulin-1 plays important roles in maintaining cardiomyocyte structure and cardiac pumping functionality and
physiology. Previously, rhNRG-1 was proven to be effective in treating heart failure in animals by reducing end-
diastolic volume (EDV) and end-systolic volume (ESV) and increasing left ventricular ejection fraction (LVEF%).
Methods A total of 44 CHF patients designated as New York Heart Association functional class II or III were enrolled in a
double-blind, randomized manner and treated with a placebo or rhNRG-1 (0.3, 0.6, or 1.2 g/kg/day) for 10
days, in addition to standard therapies. The follow-up period was 90 days; left ventricular function and structure
measured by magnetic resonance imaging were the primary end points.
Results Although not statistically different from placebo, the LVEF% was significantly increased by 27.11  31.12%
(p  0.009) at day 30 after rhNRG-1 treatment in the 0.6-g/kg group, whereas it was only increased 5.83 
25.75% in the placebo group (p  0.49). In addition, there were decreases in ESV (11.58  12.74%, p 
0.002) and EDV (5.64  10.03%, p  0.05) in the 0.6-g/kg/day group at day 30; more importantly, both
ESV and EDV levels continued to decrease at day 90 (20.79  17.03% and 14.03  13.17%, respectively),
accompanied by a sustained increase in LVEF%. This suggests that short-term treatment with rhNRG-1 results in
a long-term reversal of remodeling. The effective dose was proven to be tolerable and safe for CHF patients.
Conclusions rhNRG-1 improved the cardiac function of CHF patients by increasing the LVEF% and showed the capability of antire-
modeling by decreasing ESV and EDV compared with pre-treatment. (A Randomized, Double-Blind, Multi-Center, Pla-
cebo Parallel controlled, Standard Therapy Based Phase II Clinical Trial to Evaluate the Efficacy and Safety of Recom-
binant Human Neuregulin-1 for Injection in Patients with Chronic Heart Failure; ChiCTR-TRC-00000414) (J Am Coll
Cardiol 2010;55:1907–14) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.044o
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thronic heart failure (CHF) is a common syndrome with a
rognosis worse than most forms of cancer. Despite advances that
ave been made in heart failure (HF) drug development, the
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ge with HF are estimated to die within 8 years of diagnosis (1).
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NRG-1 Improves Cardiac Function in CHF May 4, 2010:1907–14Neuregulin (NRG)-1, a mem-
ber of the neuregulin family, is
wildly expressed, particularly in
the heart. NRG-1 has an indis-
pensable role in cardiac develop-
ment and in the maintenance of
adult heart structural and func-
tional integrity (2). Conditional
NRG-1/ErbB– deficient mice
show dilated cardiomyopathy,
suggesting that NRG-1, together
with its receptors ErbB2 and
ErbB4, plays a prominent role in
the pathogenesis of CHF (3–5).
NRG-1/ErbB signaling is acti-
vated in the early stages of CHF,
together with a profound up-
regulation of NRG-1 expression
in the left ventricular chamber.
However, in the later stages of
pump failure, both NRG-1 ex-
ression and NRG-1/ErbB signaling are inhibited (6).
vidence of NRG-1’s potential involvement in human HF
as first shown in the clinical cardiotoxicity of the ErbB2
ntibody-based compound trastuzumab, used to treat breast
ancer (7).
Enlightened by these findings, we began to investigate
he possibility of converting NRG-1 to an HF treatment
rug. First, we manufactured a recombinant human
euregulin-12 protein (rhNRG-1), which contains 61 amino
cid residues and covers the epidermal growth factor-like
omain (the domain necessary for ErbB2/ErbB4 activation).
lthough Zhao et al. (8) suggested that NRG-1 had a
ypertrophic effect on cultured rat neonatal cardiac muscle
ells, the unique effects of rhNRG-1 were observed in an in
itro experiment in 1998, as reported by Zhou et al. (9).
ardiomyocytes maintained in serum-free cultures displayed a
isrupted sarcomere arrangement, whereas rhNRG-1 treat-
ent stimulated both sarcomeric structure reorganization and
ardiac contractile unit assembly. This phenomenon was also
onfirmed by Baliga et al. (10).
Our pre-clinical work demonstrated that short-term in-
ravenous administration of rhNRG-1 attenuated patholog-
cal changes and prolonged survival in different types of
HF animal models (including CHF dogs and rats by
igation of the left anterior descending coronary artery, rapid
entricular pacing, anthracycline, and myocarditis) (11).
owever, it did not alter hemodynamic or cardiac contrac-
ility in normal animals. These beneficial effects indicated
he potential role of rhNRG-1 in addressing HF, thus
aking rhNRG-1 a promising therapeutic agent for CHF.
Encouraged by these findings, we put rhNRG-1 into a
linical trial. Since 2004, Zensun Ltd. Co. (Shanghai,
hina) has sponsored and successfully carried out a series of
linical trials. Phase I and IIa trials in China confirmed the
Abbreviations
and Acronyms
AE  adverse event
CHF  chronic heart failure
EDV  end-diastolic volume
ESV  end-systolic volume
HF  heart failure
LVEF  left ventricular
ejection fraction
MRI  magnetic resonance
imaging
NRG  neuregulin
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
rhNRG  recombinant
human neuregulinafety of rhNRG-1 in both healthy individuals and CHF ratients, showing that rhNRG-1 can effectively improve
ardiac function by increasing LVEF% in CHF patients.
ased on these findings, we embarked on Phase II clinical
rials in both China and Australia, simultaneously using
everal different protocols aimed at generating different
ndicators or evaluative end points. In this report, we
ntroduce one of these studies, which focuses on investigat-
ng the efficacy of rhNRG-1 on cardiac pump functionality
nd remodeling in CHF patients.
ethods
he Independent Ethics Committee on Human Research
f the Cardiovascular Institute and Fuwai Hospital ap-
roved the study protocol.
tudy design. This study was designed as a randomized,
ouble-blind, multicenter, background therapy-based,
lacebo-controlled, parallel group study. Target enrollment
as 44 patients at 5 clinical research units in Beijing, with
3 patients in the active treatment group and 11 in the
lacebo group.
Random allocation of patients to each treatment group
as made within each center. Specifically, 8 patients were
onsidered to be a block (4 different treatment groups of 2
atients each). Blocks were randomized to each site as a unit
ith no block divided between sites. The number of blocks
t each site depended on the rate of enrollment progress.
herefore, the numbers of patients in the groups were
lmost equal.
The doses used in this study were selected according to
ur previous results. The Phase I trial showed that 1.2
g/kg/day was the tolerable dose for bolus injection. As
evealed by animal studies, compared with the bolus injec-
ion, an 8-hour intravenous infusion per day for 10 consec-
tive days could achieve better improvement in cardiac
unction together with reduced side effects. In addition, the
hase IIa trial further confirmed that 1.2 g/kg/day was
afe for the HF patients. Thus, 1.2 g/kg/day and 10-h
ntravenous infusion were chosen as the maximum dose and
dministration route in this study.
Patients were randomly assigned to 4 groups, treated with
lacebo or rhNRG-1 (0.3, 0.6, or 1.2 g/kg/day) for 10
onsecutive days. For the patients who might need to
iscontinue the study prematurely due to intolerance, a
omprehensive safety evaluation would be performed on the
ay after the most recent administration. Both the experi-
ental and placebo groups were allowed to continue therapy
or HF with basic standard drugs, including angiotensin-
onverting enzyme inhibitors and/or beta-blocker or angio-
ensin II receptor blocker, diuretic, or digoxin.
atients. Criteria for participation in the trial included
atients with CHF (New York Heart Association func-
ional class II or III) between the ages of 18 and 65 years
ld, echocardiographically measured LVEF 40% (echo-
ardiography was only used for screening patients), in
elatively stable clinical condition (including clinical signs,
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May 4, 2010:1907–14 NRG-1 Improves Cardiac Function in CHFymptoms, and accepted standard treatment for CHF at the
arget dose or maximum tolerated dose for 1 month).
ajor exclusion criteria included magnetic resonance imag-
ng (MRI) contraindications, claustrophobia, acute myocar-
ial infarction, hypertrophic cardiomyopathy, constrictive
ericarditis, significant valve or congenital heart disease,
evere pulmonary hypertension, systolic blood pressure 90
m Hg or 160 mm Hg, severe ventricular arrhythmia,
ardiac surgery or a cerebrovascular event within the previ-
us 6 months, and pregnant women. All patients provided
itnessed written consent.
nd points and follow-up. The primary end point of the
rial was a change in LVEF%, ESV, or EDV as measured by
RI at baseline and days 11, 30, and 90. Cardiac function
lassification (NYHA), the 6-min walk test, quality of life
core, and plasma N-terminal pro–B-type natriuretic pep-
ide (NT-proBNP) were viewed as secondary efficacy end
oints. The entire study period was 90 days.
ata management and quality assurance. Computer pro-
rams combined with human review verified data quality. All
ueries were answered by the investigators, and the inspection
rocedures were repeated several times to ensure that results
ere compelling beyond reasonable doubt. All changes and
pdates were subject to recording and archiving.
Magnetic resonance images were collected in the core
aboratory and transported to Cardiolysis, Inc. (Rotterdam,
he Netherlands) (a specialist in cardiac MRI analysis) for
nalysis. Plasma NT-proBNP was tested in the core labo-
atory with dedicated kit NT-proBNP assays (Biomedica,
ienna, Austria).
tatistical analysis. Distribution of the baseline variables was
ompared using analysis of variance and chi-square tests (for
ategorical variables). Differences among groups after random-
zation were analyzed after each scheduled follow-up visit by
Demographics and Background TherapyTable 1 Demographics and Background The
Placebo
(n  11)
0.3 g/
(n  1
Age (yrs) 43 10.0 47 7.
Sex, n
Male 11 9
Female 0 2
Weight (kg) 80 12.5 72 14
NYHA functional class, n
II 7 7
III 4 4
Therapy, n
Baseline
Beta-blocker 10 9
ACEI 9 5
Devices 0 0
Adjusted
Beta-blocker 3 3
ACEI 1 1
Devices 0 0ACEI  angiotensin-converting enzyme inhibitor; NYHA  New York Heart Asomparing the mean percentage of change from the baseline
sing analysis of variance; multiple comparisons were evaluated
ith a method of contrast without adjustment. Within-group
ifferences after treatment were evaluated by paired t tests
ithout correction for multiple comparisons. Values are re-
orted as mean  SD; all p values reported are for 2-tailed
ests, and p  0.05 was considered statistically significant.
esults
atients and compliance with the treatment. Between
uly 2007 and May 2009, a total of 44 patients with NYHA
unctional class II or III stable CHF were enrolled and
andomized to 4 groups: placebo or 0.3, 0.6, and 1.2 g/kg
f rhNRG-1. There were no significant variations in demo-
raphics or background therapies among groups (Table 1).
ll enrolled patients were administered the drug for 10
onsecutive days, except patients 6066 and 6085 in the
.2-g/kg group, who withdrew on days 5 and 7, respec-
ively, due to adverse reactions, and patient 6050 in the
.6-g/kg group, who was eliminated on day 3 due to a
rotocol violation. Patient 6018 in the 0.6-g/kg group
ropped out after the 30-day follow-up (Fig. 1).
ardiac functionality assessed by MRI. Cardiac func-
ionality as measured by MRI was the primary end point of
his study. Figure 2 shows a dynamic change in LVEF%
ver the entire period of the study. Although the changes
re not statistically significant between the rhNRG-1 and
lacebo groups, there was an increase in LVEF% in the
.6-g/kg group (12.10 22.27%, p 0.12), first observed
t day 11; it became more significant at day 30 (increase of
7.11 31.12%, p 0.009). More importantly, even at day
0, 80 days after the treatment, LVEF% remained at a high
evel (increase of 31.99  44.93%, p  0.02). Throughout
0.6 g/kg
(n  11)
1.2 g/kg
(n  10)
p Value
Among Groups
39 14.5 48 12.4 0.226
10 7 0.202
1 3
77 12.2 70 15.6 0.338
9 5 0.508
2 5
10 10 0.892
10 7 0.115
0 0 —
5 4 0.948
0 0 0.721
0 0 —rapy
kg
1)
5
.5sociation.
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NRG-1 Improves Cardiac Function in CHF May 4, 2010:1907–14he study, LVEF% in the placebo group did not change
ignificantly compared with the baseline, only showing an
ncrease in LVEF% of 5.83  25.75% (p  0.49) at day 30
nd 15.05  28.29% at day 90 (p  0.16). Although not as
ramatic as what was observed for the 0.6-g/kg group, the
.3-g/kg group experienced an increase in LVEF% at day
Figure 1 Flow Diagram of the Study
*MRI data of patients who dropped out during the administration time were not in
Figure 2 Percentage of Change in LVEF% After Treatment
The graph shows the percentage of change in left ventricular ejection fraction
(LVEF%) (mean  SD) at days 11, 30, and 90 compared with day 0 (baseline).
Black line  placebo, blue line  0.3-g/kg dose, red line  0.6-g/kg dose,
and green line  1.2-g/kg dose. The tables at the bottom show the statisti-
cal results shown as the p values.f0 (11.55 16.11%, p 0.03). There was no improvement
n cardiac pumping functionality in the 1.2-g/kg group.
Together with the increase in LVEF%, there was a
endency for a time-dependent decrease in ESV and EDV
n the 0.3- and 0.6-g/kg groups. By days 30 and 90 in the
.3-g/kg group, ESV had decreased by 5.33  12.89%
nd 12.10  16.12%, respectively, and EDV had decreased
y 3.28  11.34% and 8.07  13.38%, respectively. Also at
ays 30 and 90, in the 0.6-g/kg group, ESV decreased by
1.58  12.74% and 20.79  17.03%, respectively, and
DV decreased by 5.64  10.03% and 14.03  13.17%,
espectively. Consistent with the results of changes in
VEF%, 0.6 g/kg was the most effective dose for inhib-
ting cardiac enlargement.
Despite the short period of administration, ESV and
DV were reduced in the rhNRG-1 0.6- and 0.3-g/kg
ose groups even after day 30, when heart pumping func-
ionality had already been greatly improved. Comparing the
esults of day 90 with those of day 30, ESV and EDV levels
ere further decreased (Fig. 3B). From this point, the
enefit of rhNRG-1 to inhibit or reverse the cardiac
emodeling is long-lasting. Further, there are dose-
ependent effects exhibited between 0.3 and 0.6 g/kg.
econdary efficacy end points. Considering the small
ample number, it may be difficult to generate positive
esults with respect to the 6-min walk test, quality of life,
nd NYHA functional class in this study. As estimated,
here were no significant differences between the placebo
nd rhNRG-1 treatment groups with respect to improve-
ents in 6-min walk test, quality of life, and NYHA
in the final analysis. AE  adverse event.cludedunctional class (Table 2).
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May 4, 2010:1907–14 NRG-1 Improves Cardiac Function in CHFPlasma NT-proBNP, an indicator of the prognosis, was
lso measured in this study. There was an elevation of
T-proBNP (increase of 26.79  102% compared with
aseline) in the placebo group at day 90; this elevation
eemed to be inhibited in the 0.6- and 0.3-g/kg treatment
roups (decrease of 3.5  60.07% and increase of 8.66 
4.83%, respectively, compared with baseline), as shown in
igure 4. This result indicated that rhNRG-1 might be a
avorable treatment for HF patients.
dverse events (AEs). There were 44 patients enrolled in
he study, and the incidence of AEs in the placebo, 0.3-,
.6-, and 1.2-g/kg groups was 54.44%, 63.64%,
6.67%, and 100%, respectively. The incidence of AEs
id not increase when the drug was administered at a
Figure 3 Percentage of Change in ESV and EDV After Treatmen
(A, graphs) Percentage of change in end-systolic volume (ESV) and end-diastolic v
(A, tables) Statistical results shown as the p values. (B, graphs) Percentage of ch
placebo, blue lines  0.3-g/kg dose, red lines  0.6-g/kg dose, and green linose 0.6 g/kg compared with placebo, whereas it mncreased in the 1.2-g/kg group. The mostly commonly
ccurring AEs were gastrointestinal disorders (Table 3),
uch as nausea, vomiting, poor appetite, dyspepsia, diar-
hea, and abdominal discomfort, which were well toler-
ted in most cases. Other AEs included headache,
izziness, fatigue, and palpitations, none of which wors-
ned over the period of administration. In addition, no
erious AEs occurred during this study.
Vital signs such as heart rate, blood pressure, and respi-
atory rate were tested every day before and after infusion of
he drug during the administration period, and no signifi-
ant changes were observed. Further, rhNRG-1 treatment
ad no long-term effects on vital signs, as evidenced by data
rom follow-up visits. Results showed that rhNRG-1 treat-
(EDV) (mean  SD) at days 11, 30, and 90 compared with day 0 (baseline).
in ESV and EDV (mean  SD) at day 90 compared with day 30. Black lines 
.2-g/kg dose. (B, table) Statistical results.t
olume
ange
es  1ent had no effects on the full blood count (FBC) or urine
Secondary Efficacy End PointsTable 2 Secondary Efficacy End Points
Placebo 0.3 g/kg/day 0.6 g/kg/day 1.2 g/kg/day
p Value
Among Groups
6-min walk
Baseline 413 59.9 (n  11) 394 51.9 (n  11) 451 72.3 (n  11) 432 104.7 (n  10) 0.05
Day 11 443 61.3 (n  11) 408 60.7 (n  10) 475 86.5 (n  11) 471 123.3 (n  9) 0.05
Day 30 474 54.9 (n  11) (p  0.002)* 445 53.9 (n  11) (p  0.009)* 507 65.4 (n  11) (p  0.002)* 488 78.1 (n  8) 0.05
Day 90 496 53.7 (n  11) (p  0.001)* 466 67.4 (n  11) (p  0.004)* 506 51.1 (n  9) (p  0.03) 494 76.4 (n  9) (p  0.01)* 0.05
Quality of life
Baseline 28 20.1 (n  11) 31 22.8 (n  11) 24 13.5 (n  11) 24 18.1 (n  10) 0.05
Day 11 23 17.8 (n  11) 17 14.4 (n  11) (p  0.002)* 24 13.8 (n  10) 23 21.3 (n  9) 0.05
Day 30 16 18.5 (n  11) (p  0.004)* 17 16.8 (n  11) (p  0.001)* 17 21.0 (n  11) (p  0.04)* 18 19.6 (n  8) 0.05
Day 90 13 12.9 (n  11) (p  0.002)* 16 16.1 (n  11) (p  0.009)* 14 12.6 (n  10) (p  0.002)* 13 11.6 (n  9) 0.05
NYHA functional classification
Baseline
Class I 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 0.05
Class II 7 (63.64%) 7 (63.64%) 9 (81.82%) 5 (50.00%)
Class III 4 (36.36%) 4 (36.36%) 2 (18.18%) 5 (50.00%)
Class IV 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Day 11
Class I 1 (9.09%) 1 (9.09%) 0 (0.00%) 0 (0.00%) 0.05
Class II 10 (90.91%) 7 (63.64%) 11 (100.00%) 6 (60.00%)
Class III 0 (0.00%) 3 (27.27%) 0 (0.00%) 4 (50.00%)
Class IV 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Day 30
Class I 2 (18.18%) 2 (18.18%) 1 (9.09%) 2 (22.22%) 0.05
Class II 9 (81.82%) 9 (81.82%) 10 (90.91%) 7 (77.78%)
Class III 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Class IV 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Day 90
Class I 2 (18.18%) 2 (18.18%) 1 (10.00%) 2 (22.22%) 0.05
Class II 9 (81.82%) 8 (72.73%) 9 (90.00%) 7 (77.78%)
Class III 0 (0.00%) 1 (9.09%) 0 (0.00%) 0 (0.00%)
Class IV 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Measured data of 6-min walk and quality of life reported in mean  SD. Number of patients in each New York Heart Association (NYHA) functional class, value represents the number of patients (percentage). *Statistical significance (compared with the baseline).
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May 4, 2010:1907–14 NRG-1 Improves Cardiac Function in CHFest and biochemical markers, including those for myocar-
ium evaluations.
iscussion
RG-1 has been characterized by its indispensable role during
ardiac development and in maintaining functionality. How-
ver, whether NRG-1 could be used in treating CHF patients
as not apparent. In this study, short-term administration of
hNRG-1 helped increase LVEF% and decreased ESV and
DV levels of the left ventricular chamber even 3 months after
reatment, suggesting long-term improvements of cardiac
unctionality and structure. As a result, we have been able to
rovide pioneering evidence of the application of NRG-1 in
reating CHF.
elated studies. At present, there are no drugs clinically used
o treat HF that can directly act on damaged cardiomyocytes
nd restore heart function. Our previous work obtained signif-
cant results with respect to rhNRG-1 potentially rescuing
ardiomyocytes from serum-free induced cell structure disar-
ay. At this point, we speculate that rhNRG-1 may be a
otential drug for CHF with a novel therapy mechanism,
hich may directly improve the structure of damaged cardio-
yocytes. After the positive impact of rhNRG-1 on the heart
Figure 4 Percentage of Change in
NT-proBNP Levels at Day 90
Percentage of change in N-terminal pro–B-type natriuretic peptide (NT-proBNP)
(mean  SD) at day 90 compared with day 0 (baseline). Black bar  placebo,
blue bar  0.3-g/kg dose, red bar  0.6-g/kg dose, and green bar  1.2-
g/kg dose.
ummary of AEsTable 3 Summary of AEs
Symptoms
Nausea, vomiting, poor appetite, dyspepsia, diarrhea, abdominal discomfort
Chest tightness, dyspnea, ECG changes
Headache, fatigue, excitement, hyperhidrosis
Skeletal muscle pain, fever, rashE  adverse events; ECG  electrocardiogram.as confirmed in both in vitro and in vivo animal studies,
hNRG-1 was put into clinical trials in 2004. Phase I of the
hNRG-1 clinical trial included as many as 70 healthy volun-
eers, provided a range of safe doses, and showed no significant
ide effects. Phase IIa trials were conducted in China in 2006
nd 2007; the efficacy end points showed that rhNRG-1 could
ffectively improve cardiac functionality by increasing LVEF%
Li X, Liu X, Gao R, Zhou M, unpublished data, January
008). Based on these findings, Phase II clinical trials were
onducted both in China and Australia simultaneously. The
ustralia trial varied from the China study in that it was an
pen-label study without a placebo group and has now reached
conclusion that short-term administration of rhNRG-1
esults in acute and sustained improvement in cardiac function.
fficacy end points. The Chinese Phase II clinical trial was
double-blind, multicenter, placebo-controlled trial to eval-
ate the efficacy and safety of rhNRG-1 in patients with
ystolic CHF. The primary end point results showed that
here was progressive improvement of LVEF% along with a
eduction of EDV and ESV in the 0.6-g/kg dose group
fter treatment. However, among the groups, the changes in
VEF%, ESV, and EDV were not statistically significant;
his was probably due to the small number of patients
nrolled. More encouragingly, in contrast to all other
linical drugs that might favor cardiac remodeling, only 10
ays of rhNRG-1 administration resulted in a sustained
eneficial effect on the heart. A comparison of ESV and
DV levels on day 90 with those on day 30 showed that
oth were further decreased in a dose-dependent manner for
oses between 0.3 and 0.6 g/kg. All these results suggest
hat rhNRG-1 could effectively enhance heart pumping
unctionality and, most likely, activate a reverse-remodeling
rocess of the ventricular chamber.
It will be very interesting to know how NRG-1 enhances
he heart contractility and coupling between contraction and
ompensation, and thus results in the reverse remodeling.
ur recent preliminary studies revealed that rhNRG-1
estored the disturbed intracellular Ca2 homeostasis and
nhanced myocardial contractility by suppressing protein
hosphatase 1 and 2 expression, which resulted in activation
f SERCA2a (an intracellular sarcoplasmic reticulum–
ased calcium pumper) activities (unpublished data). Fur-
hermore, in animals with CHF, rhNRG-1 activated ex-
ression of cardiac-specific myosin light chain kinase
Patent: US11/894,542), which was directly involved in
AEs
Distribution of AEs (%)
Placebo 0.3 g/kg 0.6 g/kg 1.2 g/kg
39 10.3 10.3 27.5 51.7
97 14.2 28.5 42.8 14.2
80 20.0 20.0 46.6 13.3
84 25.0 50.2 25.0 0% of
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NRG-1 Improves Cardiac Function in CHF May 4, 2010:1907–14uscle structure and contraction (12). The direct action of
hNRG-1 in cardiomyocyte structure recovery and pumping
nhancement may be an initial factor.
Although other stresses that might accelerate the develop-
ent of HF were controlled by standard HF therapies, the
njured cardiac muscles still could not be repaired by these
herapies. In contrast, rhNRG-1 treatment caused a funda-
ental change in cardiomyocytes accompanied by reduced
tress with standard therapies, which might lead to the sus-
ained improvement of both left ventricular function and
emodeling in the late phase. Interestingly, Bersell et al. (13)
ecently reported that NRG-1 promoted myocardial regener-
tion along with decreased hypertrophy around the infarcted
rea, leading to improved functionality. In the future, we would
ike to know how this muscle cell proliferation, together with
ifferentiation, works in the heart with CHF to accelerate
ardiac muscle function.
An unexpected result was that there was no improvement
n cardiac functionality in the high dose (1.2-g/kg) group.
his is probably due to the obvious side effects caused by a
igh dose of the drug. In vitro studies showed that NRG-1
ould balance beta-adrenergic activation by stimulating
arasympathetic-like activity (14). This observation was
onsistent with the most often seen side effects during
nfusion of rhNRG-1 in our trial, such as nausea and
omiting. In addition, the activation of parasympathetic
ctivity had a negative inotropic effect on the cardiac muscle,
hich might further inhibit cardiac pumping function.
afety. All adverse events were reported within 3 months
fter the initiation of the drug. There was no significant
ifference in AE incidence between rhNRG-1 (0.6 g/
g) treatment groups and the placebo group. Although an
ncreased incidence of gastrointestinal disorders occurred in
he high-dose group, there was no change in biochemical
arkers after treatment, including myocardial enzymes.
herefore, even in the high-dose group, rhNRG-1 would
ot cause organ damage or increase the risk of serious AEs.
There was a small change in the blood pressure, but most
values were 0.05, and the changes were irregularly
ncreased or decreased during the study. Although the p
alues were occasionally0.05, they were randomly distrib-
ted in the different groups including the placebo group,
nd no dose-dependent effects were observed. Thus, we
onsidered that these were the random events. Changes of
ther vital signs were similar to the blood pressure (Online
ppendix). From all of the above, we concluded that
hNRG-1 treatment had no effect on these indexes.
onclusions
hort-term administration of rhNRG-1 (0.6 g/kg) in
HF patients could result in sustained improvement of
ardiac pumping and inhibition or reversal of ventricular
emodeling compared with baseline, although these changes fere not statistically significant between NRG-1 and the
lacebo groups.
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APPENDIX
or additional material and the participating investigators and institutions
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